SUMO特异性蛋白酶1在胰腺癌组织中的表达及其临床意义

Expression of SUMO specific protease 1 in pancrestic cancer and its clinical significance

目的探讨SUMO特异性蛋白酶1(SENP1)在胰腺癌发生、发展中的作用。方法收集胰腺癌组织及其配对癌旁正常组织各44份,采用免疫组化法、Western blotting法和RT-PCR法检测SENP1蛋白和mRNA表达,并分析其表达与患者临床病理参数的关系。结果胰腺癌组织中SENP1蛋白的相对表达量、阳性表达率分别为1.18±0.11、90.9%(40/44),其配对癌旁正常组织分别为0.57±0.04、13.6%(6/44),二者比较P均<0.01。胰腺癌组织中SENP1 mRNA的相对表达量、阳性表达率分别为79.33±2.33、93.2%(41/44),其配对癌旁正常组织分别为16.67±1.20、13.6%(6/44),二者比较P均<0.01。胰腺癌组织中SENP1阳性表达与患者病理分期、血管侵犯有关(P均<0.05),与患者性别、年龄、肿瘤部位、肿瘤直径、分化程度和淋巴结转移无关(P均>0.05)。结论SENP1在胰腺癌组织中过表达,其过表达可促进胰腺癌的发生、发展。

Objective To investigate the function of SUMO specific protease 1（ SENP1） in the occurrence and development of pancreatic cancer. Methods Forty-four cases of pancreatic cancer tissues and paired adjacent tissues were collected. The protein and mRNA expression of SENP1 was detected by immunohistochemistry,Western blotting and RTPCR,and we analyzed its relationship with the clinicopathological parameters. Results The SENP1 protein expression in the pancreatic cancer tissues was higher than that in the adjacent tissues（ 1. 18 ± 0. 11 vs. 0. 57 ± 0. 04）,and the positive rate of SENP1 protein expression in the pancreatic cancer tissues was higher than that in the adjacent tissues [90. 9%（ 40 /44） vs. 13. 6%（ 6 /44） ]（ all P 0. 01）. The SENP1 mRNA expression in the pancreatic cancer tissues was higher than that in the adjacent tissues（ 79. 33 ± 2. 33 vs. 16. 67 ± 1. 20）,and the positive rate of SENP1 mRNA expression in the pancreatic cancer tissues was higher than that of the adjacent tissues [93. 2%（ 41 /44） vs. 13. 6%（ 6 /44） ]（ all P 0. 01）. The positive protein expression of SENP1 was associated with pathological stage and vascular invasion in the pancreatic cancer tissues（ all P 0. 05）. But it was not associated with gender,age,tumor location,tumor size,differentiation and lymph node metastasis（ all P 0. 05）. Conclusion SENP1 is over-expressed in the pancreatic cancer tissues and the overexpression of SENP1 promotes the occurrence and development of pancreatic cancer.